Evidence map›Paper›PMID 42774852›Full record

ArticleiScience2026

RpS19a depletion alters the hematopoietic translatome to drive tissue overgrowth.

Naomi C Mitchell, Arjun Chahal, Tanya Javaid, Katrina Woodward, Ralf B Schittenhelm, Cheng Huang, Julie Lorent, Jiwon Lee, Melanie Rug, Amee J George and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Naomi C MitchellDivision of Genome Science and Cancer, The John Curtin School of Medical Research, The Shine-Dalgarno Centre for RNA Innovation, The Australian National University, Canberra, ACT 2601, Australia.
Arjun ChahalDivision of Genome Science and Cancer, The John Curtin School of Medical Research, The Shine-Dalgarno Centre for RNA Innovation, The Australian National University, Canberra, ACT 2601, Australia.
Tanya JavaidDivision of Genome Science and Cancer, The John Curtin School of Medical Research, The Shine-Dalgarno Centre for RNA Innovation, The Australian National University, Canberra, ACT 2601, Australia.
Katrina WoodwardDivision of Genome Science and Cancer, The John Curtin School of Medical Research, The Shine-Dalgarno Centre for RNA Innovation, The Australian National University, Canberra, ACT 2601, Australia.
Ralf B SchittenhelmDepartment of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Cheng HuangDepartment of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Julie LorentDepartment of Oncology-Pathology, Science for Life Laboratory, Karolinska Institutet, 171 77 Stockholm, Sweden.
Jiwon LeeCentre for Advanced Microscopy, The Australian National University, Canberra, ACT 2601, Australia.
Melanie RugCentre for Advanced Microscopy, The Australian National University, Canberra, ACT 2601, Australia.
Amee J GeorgeDivision of Genome Science and Cancer, The John Curtin School of Medical Research, The Shine-Dalgarno Centre for RNA Innovation, The Australian National University, Canberra, ACT 2601, Australia.
Ross D HannanDivision of Genome Science and Cancer, The John Curtin School of Medical Research, The Shine-Dalgarno Centre for RNA Innovation, The Australian National University, Canberra, ACT 2601, Australia.
Ola LarssonDepartment of Oncology-Pathology, Science for Life Laboratory, Karolinska Institutet, 171 77 Stockholm, Sweden.
Anthony W PurcellDepartment of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Eduardo EyrasDivision of Genome Science and Cancer, The John Curtin School of Medical Research, The Shine-Dalgarno Centre for RNA Innovation, The Australian National University, Canberra, ACT 2601, Australia.
Nikolay ShirokikhThe Australian Centre for RNA Therapeutics in Cancer, School of Human Sciences, The University of Western Australia, Perth, WA 6009, Australia.
Teresa T BonelloDivision of Genome Science and Cancer, The John Curtin School of Medical Research, The Shine-Dalgarno Centre for RNA Innovation, The Australian National University, Canberra, ACT 2601, Australia.
Leonie M QuinnDivision of Genome Science and Cancer, The John Curtin School of Medical Research, The Shine-Dalgarno Centre for RNA Innovation, The Australian National University, Canberra, ACT 2601, Australia.
Olga ZaytsevaDivision of Genome Science and Cancer, The John Curtin School of Medical Research, The Shine-Dalgarno Centre for RNA Innovation, The Australian National University, Canberra, ACT 2601, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite ribosomal protein loss correlating with increased tumor predisposition, direct mechanisms for the counterintuitive oncogenic effect of ribosomal protein depletion have not been reported. We used genetic models to investigate ribosomal protein S19a (RpS19a) depletion in the

Indexed as

bloodDrosophilagrowth controllymph glandNEP1protein translationribosomal proteinribosomopathyRpS19a

Identifiers

PMID42774852
PMCPMC13594744

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.